Skip to main content

Advertisement

SpringerLink
Log in

TGFBR1*6A/9A polymorphism and cancer risk: a meta-analysis of 13,662 cases and 14,147 controls

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Published data on the association between TGFBR1*6A/9A polymorphism and cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. A total of 32 studies including 13,662 cases and 14,147 controls were involved in this meta-analysis. Overall, significantly elevated cancer risks were associated with TGFBR1*6A in all genetic models (for allelic effect: OR = 1.11; 95% CI = 1.03–1.21; for 6A/6A vs. 9A/9A: OR = 1.30; 95% CI = 1.01–1.69; for 9A/6A vs. 9A/9A: OR = 1.08; 95% CI = 1.01–1.15; for dominant model: OR = 1.08; 95% CI = 1.02–1.15; for recessive model: OR = 1.29; 95% CI = 1.00–1.68). In the subgroup analysis by cancer types, significant associations were found in breast cancer (for allelic effect: OR = 1.16; 95% CI = 1.01–1.34) and ovarian cancer (for allelic effect: OR = 1.24; 95% CI = 1.00–1.54; for 6A/6A vs. 9A/9A: OR = 2.34; 95% CI = 1.03–5.33). However, no significant associations were found in colorectal cancer, bladder cancer, prostate cancer and lung cancer for all genetic models. In summary, this meta-analysis suggests that the TGFBR1*6A/9A polymorphism is associated with cancer susceptibility, increasing the risk of breast and ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW (2008) An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 107:309–330

    Article  CAS  PubMed  Google Scholar 

  2. Karim-Kos HE, De Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW (2008) Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44:1345–1389

    Article  PubMed  Google Scholar 

  3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85

    Article  CAS  PubMed  Google Scholar 

  4. Ebner R, Chen RH, Shum L, Lawler S, Zioncheck TF, Lee A (1993) Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor. Science 260:1344–1348

    Article  CAS  PubMed  Google Scholar 

  5. Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS (1999) TbetaR-I (6A) is a candidate tumor susceptibility allele. Cancer Res 59:5678–5682

    CAS  PubMed  Google Scholar 

  6. Chen T, de Vries EG, Hollema H, Yegen HA, Vellucci VF, Strickler HD (1999) Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer 82:43–51

    Article  CAS  PubMed  Google Scholar 

  7. van Tilborg AA, de Vries A, Zwarthoff EC (2001) The chromosome 9q genes TGFBR1, TSC1, and ZNF189 are rarely mutated in bladder cancer. J Pathol 194:76–80

    Article  PubMed  Google Scholar 

  8. Stefanovska AM, Efremov GD, Dimovski AJ, Jasar D, Zografski G, Josifovski T (2001) TbetaR-I(6A) polymorphism is not a tumor susceptibility allele in Macedonian colorectal cancer patients. Correspondence re: B. Pasche et al. Type I TbetaR-I (6A) Is a candidate tumor susceptibility allele. Cancer Res., 58:2727–2732, 1998. Cancer Res 61:8351–8352

    CAS  PubMed  Google Scholar 

  9. Samowitz WS, Curtin K, Leppert MF, Slattery ML (2001) Uncommon TGFBRI allele is not associated with increased susceptibility to colon cancer. Genes Chromosom Cancer 32:381–383

    Article  CAS  PubMed  Google Scholar 

  10. Baxter SW, Choong DY, Eccles DM, Campbell IG (2002) Transforming growth factor beta receptor 1 polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 11:211–214

    CAS  PubMed  Google Scholar 

  11. Chen T, Jackson C, Costello B, Singer N, Colligan B, Douglass L (2004) An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder. Int J Cancer 112:420–425

    Article  CAS  PubMed  Google Scholar 

  12. Kaklamani V, Baddi L, Rosman D, Liu J, Ellis N, Oddoux C (2004) No major association between TGFBR1*6A and prostate cancer. BMC Genet 5:28

    Article  PubMed  Google Scholar 

  13. Pasche B, Kaklamani VG, Hou N, Young T, Rademaker A, Peterlongo P (2004) TGFBR1*6A and cancer: a meta-analysis of 12 case–control studies. J Clin Oncol 22:756–758

    Article  PubMed  Google Scholar 

  14. Jin Q, Hemminki K, Grzybowska E, Klaes R, Söderberg M, Zientek H (2004) Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer 112:94–99

    Article  CAS  PubMed  Google Scholar 

  15. Suarez BK, Pal P, Jin CH, Kaushal R, Sun G, Jin L (2005) TGFBR1*6A is not associated with prostate cancer in men of European ancestry. Prostate Cancer Prostatic Dis 8:50–53

    Article  CAS  PubMed  Google Scholar 

  16. Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC (2005) Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecol Oncol 97:543–549

    Article  CAS  PubMed  Google Scholar 

  17. Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C (2005) Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res 65:3454–3461

    CAS  PubMed  Google Scholar 

  18. Chen T, Jackson CR, Link A, Markey MP, Colligan BM, Douglass LE (2006) Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer. Clin Cancer Res 12:392–397

    Article  CAS  PubMed  Google Scholar 

  19. Feigelson HS, Patel AV, Diver WR, Stevens VL, Thun MJ, Calle EE (2006) Transforming growth factor beta receptor type I and transforming growth factor beta1 polymorphisms are not associated with postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 15:1236–1237

    Article  CAS  PubMed  Google Scholar 

  20. You W, Liu Z, Zhao J, Zheng M, Zheng SY, Liu X (2007) No association between TGFBR1*6A and lung cancer. J Thorac Oncol 2:657–659

    Article  PubMed  Google Scholar 

  21. Cox DG, Penney K, Guo Q, Hankinson SE, Hunter DJ (2007) TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses’ Health Study. BMC Cancer 7:175

    Article  PubMed  Google Scholar 

  22. Song B, Margolin S, Skoglund J, Zhou X, Rantala J, Picelli S (2007) TGFBR1*6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer. Br J Cancer 97:1175–1179

    Article  CAS  PubMed  Google Scholar 

  23. Skoglund J, Song B, Dalén J, Dedorson S, Edler D, Hjern F (2007) Lack of an association between the TGFBR1*6A variant and colorectal cancer risk. Clin Cancer Res 13:3748–3752

    Article  CAS  PubMed  Google Scholar 

  24. Skoglund Lundin J, Vandrovcova J, Song B, Zhou X, Zelada-Hedman M, Werelius B (2009) TGFBR1 variants TGFBR1*6A and Int7G24A are not associated with an increased familial colorectal cancer risk. Br J Cancer 100:1674–1679

    Article  CAS  PubMed  Google Scholar 

  25. Castillejo A, Rothman N, Murta-Nascimento C, Malats N, García-Closas M, Gómez-Martínez A (2009) TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. Int J Cancer 124:608–613

    Article  CAS  PubMed  Google Scholar 

  26. Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T (2009) BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat

  27. Colleran G, McInerney N, Rowan A, Barclay E, Jones AM, Curran C (2009) The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer. Breast Cancer Res Treat

  28. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129

    Article  Google Scholar 

  29. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  CAS  PubMed  Google Scholar 

  30. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    CAS  PubMed  Google Scholar 

  31. Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17

    Google Scholar 

  32. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    CAS  PubMed  Google Scholar 

  33. Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3:807–820

    Article  CAS  PubMed  Google Scholar 

  34. Jakowlew SB (2006) Transforming growth factor-b in cancer metastasis. Cancer Metastasis Rev 25:435–457

    Article  CAS  PubMed  Google Scholar 

  35. Bian Y, Kaklamani V, Reich J, Pasche B (2003) TGF-beta signaling alterations in cancer. Cancer Treat Res 115:73–94

    Article  CAS  PubMed  Google Scholar 

  36. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS (2001) Association between the T29-->C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: the study of osteoporotic fractures. JAMA 285:2859–2863

    Article  CAS  PubMed  Google Scholar 

  37. Marchand LL, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE (2004) T29C polymorphism in the transforming growth factor h1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 13:412–415

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, 510515, China

    Ru-Yan Liao, Chen Mao & Qing Chen

  2. Cancer Center, Nanjing Drum Tower Hospital, Nanjing Medical University, Nanjing, China

    Li-Xin Qiu

  3. Longgang Center for Disease Control and Prevention of Shenzhen, Shenzhen, China

    Hong Ding

  4. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China

    Hai-Feng Pan

Authors
  1. Ru-Yan Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chen Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-Xin Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hai-Feng Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qing Chen.

Additional information

Ru-Yan Liao, Chen Mao and Li-Xin Qiu contributed equally to this work and should be considered as co-first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liao, RY., Mao, C., Qiu, LX. et al. TGFBR1*6A/9A polymorphism and cancer risk: a meta-analysis of 13,662 cases and 14,147 controls. Mol Biol Rep 37, 3227–3232 (2010). https://doi.org/10.1007/s11033-009-9906-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-009-9906-7

Keywords

Search

Navigation